Purpose:
Lymphoproliferative neoplasms are the largest and most frequently diagnosed entities in the group of haema­tological malignancies. The aim of the study was to assess whether apparent diffusion coefficient (ADC) measured on the first day of the second cycle of chemotherapy could be a predictor of prognosis and of the final treatment’s outcome.

Material and methods:
The study included 27 patients with diagnosed Hodgkin’s and non-Hodgkin’s lymphoma, who had magnetic resonance (MR) performed with diffusion weighted imaging/apparent diffusion coefficient (DWI/ADC) before and on the first day of the second cycle of chemotherapy. Imaging was performed using a 1.5 T MR scanner. ADC was measured in lymphoma infiltration in the area of the lowest signal in the ADC map and the highest signal on β 800 images in post-treatment study. After that, the corresponding area was determined in a pre-treatment study and an ADC value was measured.

Results:
The difference between ADC values in pre-treatment (ADC = 720 mm²/s) and post-treatment (ADC = 1059 mm²/s) studies was statistically significant (p < 0.001). Cutoff values for estimating response to treatment were established at the level of ADC 1080 mm²/s, and ADC to muscle ratio at 0.82 in post-treatment study. Patients with ADC > 752 mm²/s before treatment manifested lower probability of progression than patients with ADC < 752 mm²/s.

Conclusions:
ADC measurement’s before treatment and on the first day of the second cycle of chemotherapy can be used as a prognostic marker in lymphoma therapy. ADC values lower than 1080 mm²/s and an increase of the ratio after the treatment can be considered as a marker of disease progression.